Associations of Serum Thyrotropin Concentrations with Recurrence and Death in Differentiated Thyroid Cancer
Open Access
- 1 July 2007
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 92 (7) , 2610-2615
- https://doi.org/10.1210/jc.2006-2566
Abstract
Objective: The relation between serum TSH levels and risk for recurrence or thyroid carcinoma-related death in patients with differentiated thyroid carcinoma has only been studied to a limited extent. Design: We conducted a single-center observational study in 366 consecutive patients with differentiated thyroid carcinoma, who had all been treated according to the same protocol for initial therapy and follow-up. Median duration of follow-up was 8.85 yr. Methods: The relation between summarizing variables of unstimulated serum TSH concentrations (25th, 50th, and 75th percentiles, the percentage of suppressed and unsuppressed TSH values) and risk for recurrence or thyroid carcinoma-related death was analyzed by Cox survival analyses in patients with at least four TSH measurements. Results: In Cox regression analysis, we found a positive association between serum TSH concentrations and risk for thyroid carcinoma-related death and relapse, even in initially cured patients. The median of the individual TSH concentrations was the best indicator for thyroid carcinoma-related death (hazard ratio 2.03; confidence interval 1.22–3.37) and relapse (hazard ratio 1.41; confidence interval 1.03–1.95). A threshold of 2 mU/liter differentiated best between relapse-free survival and thyroid carcinoma-related death or relapse. Conclusion: Our study supports current guidelines, which advise to aim at TSH levels in the low normal range in cured low-risk patients, whereas TSH levels should be suppressed in noncured or high-risk patients.Keywords
This publication has 21 references indexed in Scilit:
- Outcomes of Patients with Differentiated Thyroid Carcinoma Following Initial TherapyThyroid®, 2006
- European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epitheliumActa Endocrinologica, 2006
- The Effects of Thyrotropin-Suppressive Therapy on Bone Metabolism in Patients with Well-Differentiated Thyroid CarcinomaThyroid®, 2006
- Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines TaskforceThyroid®, 2006
- Thyroid-hormone therapy and thyroid cancer: a reassessmentNature Clinical Practice Endocrinology & Metabolism, 2005
- Better Yield of 18Fluorodeoxyglucose-Positron Emission Tomography in Patients with Metastatic Differentiated Thyroid Carcinoma during Thyrotropin StimulationThyroid®, 2002
- Thyrotropin Suppression and Disease Progression in Patients with Differentiated Thyroid Cancer: Results from the National Thyroid Cancer Treatment Cooperative RegistryThyroid®, 1998
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerThe American Journal of Medicine, 1994
- Growth Regulation of Normal Thyroids and Thyroid Tumors in ManPublished by Springer Nature ,1990
- METASTATIC CARCINOMA OF THE THYROID SUCCESSFULLY TREATED WITH THYROXINEThe Lancet, 1954